Several MET inhibitors, including crizotinib, are currently under evaluation for the treatment of NSCLC patients with METex14 skipping and capmatinib was recently approved by FDA to treat this alteration in NSCLC. This evidence concerns the gene MET and non-small cell lung carcinoma.